Indication: Glioblastoma
Title: KING: A Phase 2 Study Evaluating the Efficacy and Safety of selinexor (KPT-330) in Patients With Recurrent Gliomas
Drug: selinexor

Rights

Drug: selinexor

PreclinicalPhase IPhase IIPhase III
Preclinical
Phase I
Phase II
Phase III